Aridis Pharmaceuticals logo
Aridis Pharmaceuticals ARDS

Quarterly report 2023-Q3
added 11-06-2023

report update icon

Aridis Pharmaceuticals Financial Statements 2011-2026 | ARDS

Annual Financial Statements Aridis Pharmaceuticals

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

4.13 M 22.2 M 17.4 M 60 M 28.8 M - - - - - - -

Shares

18.8 M 12.3 M 2.48 M 8.46 M 3.15 M - - - - - - -

Historical Prices

0.22 1.81 7.02 6.91 8.36 - - - - - - -

Net Income

-30.4 M -42.2 M -22.3 K -29.7 M -22.1 M -24.7 M -8.42 M - - - - -

Revenue

3.09 M 1.54 M 1 K 1.02 M 2.76 M 860 K 2.27 M - - - - -

Gross Profit

- - 1 K - - 860 K 342 K - - - - -

Operating Income

-30 M -42.7 M -22.4 M -29.1 M -24.1 M -19.7 M - - - - - -

EBITDA

-29.5 M -42.3 M -22.1 K -28.7 M -23.8 M -19.7 M -7.86 M - - - - -

Operating Expenses

- - 23.4 K 30.1 M 26.9 M 20.6 M 8.23 M - - - - -

General and Administrative Expenses

7.16 M 7.31 M 6.44 M 6.03 M 3.87 M 3.16 M 1.96 M - - - - -

All numbers in USD currency

Quarterly Income Statement Aridis Pharmaceuticals

2023-Q3 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

37.4 M 27 M 17.7 M 17.7 M 17.7 M 17.7 M 12.5 M 11.2 M 10.2 M 10.1 M 8.92 M 8.92 M 8.92 M 8.92 M 8.69 M 8.11 M 8.11 M 8.1 M 4.02 M 166 K 166 K 166 K 166 K 166 K - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

-83 K - -8.24 M -7.98 M -7.77 M - -21 M -5.49 M -6.89 M - -5.79 M -4.22 M -6.5 M - -7.59 M -8.38 M -8.06 M - -7.91 M -1.42 M -7.33 M - -5.42 M -6.08 M - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

417 K - 399 K 292 K 1.19 M - 515 K 33 K - - 1 M 1 M -9 K - 1.02 M 1.02 M 1.02 M - 1.02 M 22 K 322 K - 22 K 22 K - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-869 K - -7.41 M -7.74 M -7.42 M - -21 M -6.23 M -6.9 M - -5.79 M -4.23 M -6.56 M - -7.4 M -8.27 M -7.74 M - -6.62 M -4.55 M -7.37 M - -5.49 M -3.98 M - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

-811 K - -7.29 M -7.48 M -7.29 M - -20.7 M -6.05 M -6.81 M - -5.54 M -4.06 M -6.47 M - -7.14 M -8.1 M -7.65 M - -6.42 M -4.43 M -7.32 M - -5.46 M -3.97 M - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

1.29 M - 7.81 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

1.11 M - 1.69 M 1.68 M 2.16 M - 1.7 M 1.69 M 1.94 M - 1.63 M 1.58 M 1.64 M - 1.38 M 1.61 M 1.64 M - 735 K 687 K 1.07 M - 649 K 829 K - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Aridis Pharmaceuticals ARDS
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Aridis Pharmaceuticals plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
BioNTech SE BioNTech SE
BNTX
$ 96.98 -6.26 % $ 27.2 B germanyGermany
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 5.16 4.56 % $ 820 M britainBritain
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Cerus Corporation Cerus Corporation
CERS
$ 2.73 34.49 % $ 520 M usaUSA
ACADIA Pharmaceuticals ACADIA Pharmaceuticals
ACAD
$ 21.96 -2.2 % $ 3.64 B usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
AstraZeneca PLC AstraZeneca PLC
AZN
- - $ 96.9 B britainBritain
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
Berkeley Lights Berkeley Lights
BLI
- -7.31 % $ 87 M usaUSA
Calithera Biosciences Calithera Biosciences
CALA
- -10.95 % $ 876 K usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
CymaBay Therapeutics CymaBay Therapeutics
CBAY
- - $ 3.45 B usaUSA
ChemoCentryx ChemoCentryx
CCXI
- - $ 3.74 B usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Cardiff Oncology Cardiff Oncology
CRDF
$ 1.71 -1.45 % $ 114 M usaUSA
Caladrius Biosciences Caladrius Biosciences
CLBS
- -16.75 % $ 25.8 M usaUSA
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
- - $ 231 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
- -2.5 % $ 5.88 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Deciphera Pharmaceuticals Deciphera Pharmaceuticals
DCPH
- - $ 2.18 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Editas Medicine Editas Medicine
EDIT
$ 2.92 -2.83 % $ 259 M usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
- - $ 2.02 B usaUSA
Edesa Biotech Edesa Biotech
EDSA
$ 17.54 -4.02 % $ 56.1 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 3.0 -5.96 % $ 4.94 M israelIsrael
Eiger BioPharmaceuticals Eiger BioPharmaceuticals
EIGR
- -9.21 % $ 2.55 M usaUSA
Eloxx Pharmaceuticals Eloxx Pharmaceuticals
ELOX
- -5.68 % $ 8.28 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Evogene Ltd. Evogene Ltd.
EVGN
$ 0.79 1.66 % $ 27.9 M israelIsrael
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA